The p53 R267W mutation intervenes p21-mediated cell cycle arrest and promotes proliferation and migration of lung cancer cells
Received date: 2025-10-15
Revised date: 2025-12-22
Online published: 2025-12-29
Supported by
National Natural Science Foundation of China(81972312);Hunan Provincial Natural Science Foundation of China(2025JJ80166);Central South University Graduate Educational Reform Research Program(2025JGB159)
Pathogenic germline variants in TP53 constitute the central etiological driver of hereditary tumor predisposition disorders syndromes. The oncogenic mechanisms of hotspot mutations in the DNA-binding domain of p53 are well-established. However, the functional consequences of non-hotspot missense mutations remain incompletely understood. In this study, we characterized the molecular pathogenesis and clinical significance of the p53 non-hotspot mutation p.Arg267Trp (p.R267W). In addition, evolutionary conservation analysis, structural prediction, and functional assays including CCK-8 cell proliferation, clonogenic assay, Transwell migration, wound healing assay, qPCR, Western blot, single luciferase reporter assay, and flow cytometry techniques were performed to assess the impact of R267W on TP53 target gene (CDKN1A) regulation and tumor-suppressive phenotypes (proliferation, colony formation, migration) in non-small cell lung cancer models (A549/NCI-H1299). Experiments confirmed that the mutant does not affect the p53 protein stability. The impairment of protein function is hypothesized to result from the disruption of the DNA-binding domain conformation. Experimental evidence suggested that the mutant TP53 exhibited significantly reduced transcriptional activity (P<0.001), resulting in a concomitant reduction in CDKN1A mRNA expression and diminished cell cycle arrest capability when compared to wild type. At the tumor-suppressive functional level, the R267W mutant significantly reduced inhibition rates of non-small cell lung cancer cell proliferation, colony formation, and migration relative to wild type (P<0.05). This study reveals that the R267W variant drives cell cycle dysregulation and malignant phenotypes in lung cancer by disrupting TP53’s transcriptional functions. These findings establish a molecular basis for the pathogenic classification of TP53 variants of uncertain clinical significance.
Jianing Zhao, Jinzheng Wu, Shubing Zhang . The p53 R267W mutation intervenes p21-mediated cell cycle arrest and promotes proliferation and migration of lung cancer cells[J]. Hereditas(Beijing), 2026 , 48(6) : 589 -600 . DOI: 10.16288/j.yczz.25-222
| [1] | Mckay GE, Zakas AL, Osman F, Parkes A. Factors affecting genetic consultation in adolescent and young adult patients with sarcoma. J Natl Compr Canc Netw, 2021, 1-8. |
| [2] | Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer, 2014, 14(5): 359-370. |
| [3] | Lu SQ, Jia ST, Luo Y. Recent advances in mutant p53 and novel personalized strategies for cancer therapy. Hereditas (Beijing), 2011, 33(6): 539-548. |
| 陆思千, 贾舒婷, 罗瑛. 突变p53功能研究新进展与个性化的肿瘤治疗新策略. 遗传, 2011, 33(6): 539-548. | |
| [4] | Marvalim C, Datta A, Lee SC. Role of p53 in breast cancer progression: an insight into p53 targeted therapy. Theranostics, 2023, 13(4): 1421-1442. |
| [5] | Hassin O, Oren M. Drugging p53 in cancer: one protein, many targets. Nat Rev Drug Discov, 2023, 22(2): 127-144. |
| [6] | Wang HL, Guo M, Wei HD, Chen YH. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther, 2023, 8(1): 92. |
| [7] | Nian ZG, Dou YC, Shen YQ, Liu JT, Du XH, Jiang Y, Zhou YG, Fu BQ, Sun R, Zheng XH, Tian ZG, Wei HM. Interleukin-34-orchestrated tumor-associated macrophage reprogramming is required for tumor immune escape driven by p53 inactivation. Immunity, 2024, 57(10): 2344-2361.e2347. |
| [8] | Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science, 1990, 250(4985): 1233-1238. |
| [9] | Zhao S, Wen HY, Wang BQ, Xiong QL, Li LX, Cheng AL. p53: a player in the tumor microenvironment. Oncol Res, 2025, 33(4): 795-810. |
| [10] | Stein Y, Rotter V, Aloni-Grinstein R. Gain-of-Function Mutant p53: all the roads lead to tumorigenesis. Int J Mol Sci, 2019, 20(24): 6197. |
| [11] | Joerger AC, Stiewe T, Soussi T. TP53: the unluckiest of genes? Cell Death Differ, 2025, 32(2): 219-224. |
| [12] | Funk JS, Klimovich M, Drangenstein D, Pielhoop O, Hunold P, Borowek A, Noeparast M, Pavlakis E, Neumann M, Balourdas DI, Kochhan K, Merle N, Bullwinkel I, Wanzel M, Elmshäuser S, Teply-Szymanski J, Nist A, Procida T, Bartkuhn M, Humpert K, Mernberger M, Savai R, Soussi T, Joerger AC, Stiewe T. Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations. Nat Genet, 2025, 57(1): 140-153. |
| [13] | Li DH, Zhang LQ, He FC. Advances on mutant p53 research. Hereditas (Beijing), 2008, 30(6): 697-703. |
| 李大虎, 张令强, 贺福初. 突变体p53研究进展. 遗传, 2008, 30(6): 697-703. | |
| [14] | Kennedy MC, Lowe SW. Mutant p53: it's not all one and the same. Cell Death Differ, 2022, 29(5): 983-987. |
| [15] | Chen XH, Zhang TT, Su W, Dou ZH, Zhao DP, Jin XD, Lei HW, Wang J, Xie XD, Cheng B, Li Q, Zhang H, Di CX. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis, 2022, 13(11): 974. |
| [16] | Leroy B, Fournier JL, Ishioka C, Monti P, Inga A, Fronza G, Soussi T. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res, 2013, 41(Database issue): D962-D969. |
| [17] | Muller PAJ, Vousden KH. p53 mutations in cancer. Nat Cell Biol, 2013, 15(1): 2-8. |
| [18] | Shah MV, Arber DA, Hiwase DK. TP53-Mutated Myeloid Neoplasms: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol, 2025, 100 Suppl 4(Suppl 4): 88-115. |
| [19] | Kotler E, Shani O, Goldfeld G, Lotan-Pompan M, Tarcic O, Gershoni A, Hopf TA, Marks DS, Oren M, Segal E. A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation. Mol Cell, 2018, 71(5): 873. |
| [20] | Zhang C, Liu J, Xu DD, Zhang TL, Hu WW, Feng ZH. Gain-of-function mutant p53 in cancer progression and therapy. J Mol Cell Biol, 2020, 12(9): 674-687. |
| [21] | Liu YQ, Su ZY, Tavana O, Gu W. Understanding the complexity of p 53 in a new era of tumor suppression. Cancer Cell, 2024, 42(6): 946-967. |
| [22] | Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol, 2008, 9(5): 402-412. |
| [23] | Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p 53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science, 1994, 265(5170): 346-355. |
| [24] | Su ZY, Kon N, Yi JJ, Zhao HQ, Zhang WW, Tang QS, Li H, Kobayashi H, Li ZM, Duan SF, Liu YQ, Olive KP, Zhang ZG, Honig B, Manfredi JJ, Rustgi AK, Gu W. Specific regulation of BACH1 by the hotspot mutant p53R175H reveals a distinct gain-of-function mechanism. Nat Cancer, 2023, 4(4): 564-581. |
| [25] | Klemm N, Schimmer RR, Konrad NK, Thelen F, Fullin J, Topçu E, Koch C, Treacy M, Leventhal MJ, Bühler MM, Lysenko V, Theocharides APA, Kurppa KJ, Balabanov S, Baubec T, Krivtsov AV, Miller PG, Armstrong SA, Ebert BL, Manz MG, Nombela-Arrieta C, Boettcher S. The prolonged half-life of the p53 missense variant R248Q promotes accumulation and heterotetramer formation with wild-type p53 to exert the dominant-negative effect. Cancer Res, 2025, 85(11): 1978-1996. |
| [26] | Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol, 2010, 2(1): a001008. |
| [27] | Pan ZZ, Wang K, Wang XN, Jia ZR, Yang YQ, Duan YL, Huang LZ, Wu ZX, Zhang JY, Ding XS. Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression. Mol Cancer, 2022, 21(1): 77. |
| [28] | Feng C, Kong DM, Tong BH, Liang YH, Xu FY, Yang YY, Wu YY, Chi XD, Wei PF, Yang Y, Zhang GL, Tian G, Xu ZW. Hypoxia-triggered ERRα acetylation enhanced its oncogenic role and promoted progression of renal cell carcinoma by coordinating autophagosome-lysosome fusion. Cell Death Dis, 2025, 16(1): 23. |
| [29] | Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu YL, Bhagat G, Richards KL, Hsi ED, Zhao XF, Choi WWL, Zhao XY, Van Krieken JH, Huang Q, Huh J, Ai WY, Ponzoni M, Ferreri AJM, Zhou F, Kahl BS, Winter JN, Xu W, Li JY, Go RS, Li Y, Piris MA, Møller MB, Miranda RN, Abruzzo LV, Medeiros LJ, Young KH. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP:report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2012, 120(19): 3986-3996. |
| [30] | Fang Y, Zhang MC, He Y, Li C, Fang H, Xu PP, Cheng S, Zhao Y, Feng Y, Liu Q, Wang L, Zhao WL. Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma. Signal Transduct Target Ther, 2023, 8(1): 381. |
| [31] | Abduljaleel Z. Molecular insights into TP53 mutation (p. Arg267Trp) and its connection to choroid plexus carcinomas and Li-Fraumeni syndrome. Genes Genomics, 2024, 46(8): 941-953. |
| [32] | Ma FY, Laster K, Dong ZG. The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations. Nat Commun, 2022, 13(1): 5651. |
| [33] | Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263. |
| [34] | Levine AJ. The p53 tumor-suppressor gene. N Engl J Med, 1992, 326(20): 1350-1352. |
| [35] | Engeland K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ, 2022, 29(5): 946-960. |
| [36] | Klimovich B, Merle N, Neumann M, Elmshäuser S, Nist A, Mernberger M, Kazdal D, Stenzinger A, Timofeev O, Stiewe T. p53 partial loss-of-function mutations sensitize to chemotherapy. Oncogene, 2022, 41(7): 1011-1023. |
| [37] | Fulci G, Ishii N, Maurici D, Gernert KM, Hainaut P, Kaur B, Van Meir EG. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p 53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion. Cancer Res, 2002, 62(10): 2897-2905. |
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号
